PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
Therapy Focus: Neuropathic Pain
From issue 66 of the PharmaDeals Review (2005-12-01)
While a wide range of drugs, from NSAIDs to opioids, have been developed to treat nociceptive pain, sufferers of neuropathic pain have had to rely on drugs that were developed to treat other conditions such as depression and epilepsy. Although the developers of these blockbuster drugs have extended their life spans with patents on improved re-formulations, some of the most interesting therapies in development for the treatment of neuropathic pain are derived from novel sources such as venomous marine snails and the extract of red chilli peppers. As Bayer has found, the small biotechs that discover these drugs are ideal partners for the big pharma companies who can recognise their potential.
Available as PDF
(Subscribers only)
Agensys Fuels Merck & Co.'s Cancer Ambitions
From issue 65 of the PharmaDeals Review (2005-11-01)
In an endeavour to boost its oncology effort, Merck & Co. has added the first clinical-stage monoclonal antibody to its development pipeline in the form of Agensys' AGS-PSCA, which targets prostate stem cell antigen (PSCA) and is in Phase I development for advanced prostate cancer. This feature considers how the agreement will stand to benefit both parties.
Available as PDF
(Subscribers only)
Galapagos: An Evolving Company
From issue 65 of the PharmaDeals Review (2005-11-01)
The recent acquisition of UK-based BioFocus by the target identification and validation specialist Galapagos signals the latter's transformation into a relatively unusual kind of company: a fully integrated European biotech specialising in drug discovery. This feature explores some of the history of Galapagos, and the rationale behind the company's latest deal.
Available as PDF
(Subscribers only)
Trends within the Drug Delivery Sector
From issue 65 of the PharmaDeals Review (2005-11-01)
This article is adapted from the PharmaVentures Drug Delivery Report Autumn/Winter 2005. It assesses the trends in terms of the types of deals made and the types of companies participating, and analyses and discusses the possible reasons behind these. Future trends are predicted.
Available as PDF
(Subscribers only)
Therapy Focus: Colorectal Cancer
From issue 65 of the PharmaDeals Review (2005-11-01)
Colorectal cancer is one of the most commonly diagnosed cancers. Treatment options have increased dramatically over the past 10 years, but those available remain unsatisfactory. Chemotherapy continues as the main treatment, with targeted monoclonal antibody therapies added to cytotoxic regimens for more advanced disease. Treatment is also evolving as new chemotherapy combinations are investigated and novel products are introduced.
Last Issue PDF
RSS